Breaking Finance News

Zacks Investment Research upgraded Aclaris Therapeutics Inc (NASDAQ:ACRS) to Hold in a statement released earlier today.

Yesterday Aclaris Therapeutics Inc (NASDAQ:ACRS) traded -0.68% lower at $24.86. ACRS’s 50-day average is $21.38 and its two hundred day average is $19.76. The last stock close price is up 25.79% from the 200-day moving average, compared to the S&P 500 Index which has decreased -0.01% over the same period. Trade Volume was up over the average, with 264,880 shares of ACRS changing hands over the typical 76,362

Zacks Investment Research has upgraded Aclaris Therapeutics Inc (NASDAQ:ACRS) to Hold in a report released on 9/23/2016.

Previously on Monday September 19, 2016, Jefferies & Co reported about Aclaris Therapeutics Inc (NASDAQ:ACRS) increased the target price from $23.00 to $31.00 that suggested an upside of 0.26%.

Performance Chart

Aclaris Therapeutics Inc (NASDAQ:ACRS)

With a total market value of $0, Aclaris Therapeutics Inc has with a 52 week low of $10.99 and a 52 week high of $33.88 .

In addition to Zacks Investment Research reporting its stock price target, a total of 3 brokerages have issued a ratings update on the company. The average stock price target is $26.33 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and lastly zero analysts rating the company a sell.

General Company Details For Aclaris Therapeutics Inc (NASDAQ:ACRS)

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company's lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK), a non-malignant skin tumor. The Company has completed over three Phase II clinical trials of A-101 in over 300 patients with SK. The Company has initiated a Phase II clinical trial of A-101 for the treatment of common warts. In addition to A-101, the Company is also developing A-102, a topical gel dosage form of hydrogen peroxide, for the treatment of both SK and common warts. It has in-licensed the rights to inhibitors of the Janus kinase (JAK) family of enzymes, for specified dermatological conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *